In pancreatic cancer, Gli3 mediates cell survival and increased cell resistance to cyclopamine, while in colorectal cancer, Gli3 augments tumorigenicity by up-regulating adherence-related genes 69,70. This evidence concerns the gene GLI3 and familial pancreatic carcinoma.